Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome

European Journal of Endocrinology

Volumn 159, Issue 4, 2008, Pages 399-406

  Jensterle, Mojca ^a   Sebestjen, Miran ^a   Janez, Andrej ^a   Prezelj, Janez ^a   Kocjan, Tomaz ^a   Keber, Irena ^a   Pfeifer, Marija ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; C REACTIVE PROTEIN; GLYCERYL TRINITRATE; INSULIN SENSITIZING AGENT; LIPID; METFORMIN; ROSIGLITAZONE; TESTOSTERONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ARTERY DILATATION; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; BRACHIAL ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; MENSTRUAL CYCLE; MENSTRUATION; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; BLOOD; CARDIOVASCULAR DISEASE; DRUG EFFECT; METABOLISM; PHYSIOLOGY; VASCULAR ENDOTHELIUM; VASODILATATION;

ANDROGENS; BRACHIAL ARTERY; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; FEMALE; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPIDS; MENSTRUAL CYCLE; METFORMIN; POLYCYSTIC OVARY SYNDROME; THIAZOLIDINEDIONES; VASODILATION;

EID: 54049152752     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-08-0507     Document Type: Article

References (54)

1. Franks S. Polycystic ovary syndrome. New England Journal of Medicine 1995 333 853-856.
2. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES & Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. Journal of Clinical Endocrinology and Metabolism 2004 89 2745-2749.
3. Dunaif A, Segal KR, Futterweit W & Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989 38 1165.
4. Legro RS, Kunselman AR & Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. American Journal of Medicine 2001 111 607-613.
5. Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV & Go AS. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2006 91 1357-1363.
6. Orio F Jr, Palomba S, Spinelli L, Cascella T, Tauchmanovà L, Zullo F, Lombardi G & Colao A. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. Journal of Clinical Endocrinology and Metabolism 2004 89 3696-3701.
7. Orio F Jr, Palomba S, Cascella T, De Simone B, Di Biase S, Russo T, Labella D, Zullo F, Lombardi G & Colao A. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2004 89 4588-4593.
8. Vryonidou A, Papatheodorou A, Tavridou A, Terzi T, Loi V, Vatalas IA, Batakis N, Phenekos C & Dionyssiou-Asteriou A. Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2005 90 2740-2746.
9. Lakhani K, Hardiman P & Seifalian AM. Intima-media thickness of elastic and muscular arteries of young women with polycystic ovaries. Atherosclerosis 2004 175 353-359.
10. Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE & Kuller LH. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arteriosclerosis, Thrombosis, and Vascular Biology 2000 20 2414-2421.
11. Shroff R, Kerchner A, Maifeld M, Van Beek EJ, Jagasia D & Dokras A. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. Journal of Clinical Endocrinology and Metabolism 2007 92 4609-4614.
12. Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK & Baron AD. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001 103 1410-1415.
13. Tarkun I, Arslan BC, Cantürk Z, Türemen E, Sahin T & Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. Journal of Clinical Endocrinology and Metabolism 2004 89 5592-5596.
14. Kelly CJG, Speirs A, Gould GW, Petrie JR, Lyall H & Connell JMC. Altered vascular function in young women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2002 87 742-746.
15. Azziz A. Long term morbidity of PCOS. In The Polycystic Ovary Syndrome: Current Concepts on Pathogenesis and Clinical Care, p 124. Ed. R Azziz, New York: Springer Science+Business Media, LCC, 2007.
16. Bonetti PO, Lerman LO & Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arteriosclerosis, Thrombosis, and Vascular Biology 2003 23 168-175.
17. Celermajer DS. Endothelial dysfunction: does it matter? Is it reversible? Journal of the American College of Cardiology 1997 30 325-333.
18. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK & Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992 340 1111-1115.
19. Chauhan A, Mullins PA, Taylor G, Petch MC & Schofield PM. Both endothelium-dependent and endothelium-independent function is impaired in patients with angina pectoris and normal coronary angiograms. European Heart Journal 1997 18 60-68.
20. Abdu TAM, Elhadd T, Pfeifer M & Clayton RN. Endothelial dysfunction in endocrine disease. Trends in Endocrinology and Metabolism 2001 12 257-265.
21. Ross R. Atherosclerosis: an inflammatory disease. New England Journal of Medicine 1999 340 115-126.
22. Laakso M, Edelman SV, Brechtel G & Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. Journal of Clinical Investigation 1990 85 1844-1852.
23. Scherrer U, Randin D, Vollenweider P, Vollenweider L & Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. Journal of Clinical Investigation 1994 94 2511-2515.
24. Arcaro G, Zamboni M, Rossi L, Turcato E, Covi G, Armellini F, Bosello O & Lechi A. Body fat distribution predicts the degree of edothelial dysfunction in uncomplicated obesity. International Journal of Obesity and Related Metabolic Disorders 1999 23 936-942.
25. Steinberg HO, Chaker H, Learning R, Johnson A, Brechtel G & Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. Journal of Clinical Investigation 1996 97 2601-2610.
26. Harborne L, Fleming R, Lyall H, Norman J & Sattar N. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet 2003 361 1894-1901.
27. Lord JM, Flinght IH & Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003 327 951-953.
28. Cataldo NA, Abbasi F, McLaughlin TL, Lamendola C & Reaven GM. Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone. Fertility and Sterility 2001 76 1057-1059.
29. Ghazeeri G, Kutteh WH, Bryer-Ash M, Haas D & Ke RW. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertility and Sterility 2003 79 562-566.
30. Sepilian V & Nagamani M. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. Journal of Clinical Endocrinology and Metabolism 2005 90 60-65.
31. Cataldo NA, Abbasi F, McLaughlin TL, Basina M, Fechner PY, Giudice LC & Reaven GM. Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome. Human Reproduction 2006 21 109-120.
32. Rautio K, Tapanainen JS, Ruokonen A & Morin-Papunen LC. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. Human Reproduction 2006 21 1400-1407.
33. Majuri A, Santaniemi M, Rautio K, Kunnari A, Vartiainen J, Ruokonen A, Kesaniemi YA, Tapanainenm JS, Ukkola O & Morin-Papunen L. Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in over-weight women with PCOS: a randomized placebo-controlled study. European Journal of Endocrinology 2007 156 263-269.
34. Zawadzki JK & Dunaif A. Diagnostic criteria for polycystic ovary syndrome. In Polycystic Ovary Syndrome, pp 377-384. Eds A Dunaif, F Haseltine & GR Merriam, Boston: Blackwell Scientific Publications, 1992.
35. Azziz R. Definition, diagnosis, and epidemiology of the polycystic ovary syndrome. In The Polycystic Ovary Syndrome: Current Concepts on Pathogenesis and Clinical Care, p 5. Ed. R Azziz, New York: Springer Science+ Business Media, LCC, 2007.
36. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419.
37. Hedblad B, Nilsson P, Janzon L & Berglund G. Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmo, Sweden. Diabetic Medicine 2000 17 299-307.
38. Zeiher AM, Schächinger V & Minners J. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function. Circulation 1995 92 1094-1100.
39. Diamanti-Kandarakis E, Alexandraki K, Protogerou A, Piperi C, Papamichael C, Aessopos A, Lekakis J & Mavrikakis M. Metformin administration improves endothelial function in women with polycystic ovary syndrome. European Journal of Endocrinology 2005 52 749-756.
40. Orio F Jr, Palomba S, Cascella T, De Simone B, Manguso F, Savastano, S, Russo T, Tolino A, Zullo F, Lombardi G, Azziz R & Colao A. Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. Journal of Clinical Endocrinology and Metabolism 2005 90 6072-6076.
41. Lowenstein L, Damti A, Pillar G, Shott S & Blumenfeld Z. Evaluation of endothelial function in women with polycystic ovary syndrome. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2007 134 208-212.
42. Meyer C, McGrath BP & Teede HJ. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 2007 30 471-478.
43. Tarkun I, Cetinarslan B, Türemen E, Sahin T, Cantürk Z & Komsuoglu B. Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome. European Journal of Endocrinology 2005 153 115-121.
44. Sourij H, Zweiker R & Wascher TC. Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. Diabetes Care 2006 29 1039-1045.
45. Kim J, Montagnani M, Koh KK & Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction. Circulation 2006 113 1888-1904.
46. Diamanti-Kandarakis E, Spina G, Kouli C & Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. Journal of Clinical Endocrinology and Metabolism 2001 86 4666-4673.
47. Ki-Jarvinen H. Insulin resistance and endothelial dysfunction. Best Practice and Research. Clinical Endocrinology and Metabolism 2003 17 411-430.
48. Seligman B, Biolo A, Polanczyk C, Gross J & Clausell N. Increased plasma levels of endothelin 1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2000 23 1395-1400.
49. Landin K, Tengborn L & Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. Journal of Internal Medicine 1991 229 181-187.
50. Pasceri V, Willerson JT & Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000 102 2165-2168.
51. Sjöholm A & Nyström T. Endothelial inflammation in insulin resistance. Lancet 2005 365 610-612.
52. Orio F Jr, Palomba S, Cascella T, De Simone B, Di Biase S, Russo T, Labella D, Zullo F, Lombardi G & Colao A. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2004 89 4588-4593.
53. Nestler JE. Metformin for the treatment of the polycystic ovary syndrome. New England Journal of Medicine 2008 358 47-54,
54. Balen A. Strategies for ovulation induction in the management of anovulatory polycystic ovary syndrome. In The Polycystic Ovary Syndrome: Current Concepts on Pathogenesis and Clinical Care, p 110. Ed. R Azziz, New York: Springer Science + Business Media, LCC, 2007.